![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00081510 |
Primary Objective(s):
Secondary Objective(s):
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: Lonafarnib plus Anastrozole Drug: Placebo plus Anastrozole |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer |
Estimated Enrollment: | 124 |
Study Start Date: | December 2003 |
Estimated Study Completion Date: | October 2008 |
Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Lonafarnib plus Anastrozole: Experimental |
Drug: Lonafarnib plus Anastrozole
Lonafarnib 200 mg PO BID beginning on Cycle 1 Day 1 and continuously until Progression of Disease, unacceptable toxicity, or other discontinuation criteria. Subjects will be treated concomitantly with anastrozole (1 mg PO QD) continuously.
|
Placebo plus Anastrozole: Active Comparator |
Drug: Placebo plus Anastrozole
Placebo PO BID beginning on Cycle 1 Day 1 and continuously until Progression of Disease, unacceptable toxicity, or other discontinuation criteria. Subjects will be treated concomitantly with anastrozole (1 mg PO QD) continuously.
|
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics:
Exclusion Criteria:
Responsible Party: | Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group ) |
Study ID Numbers: | P03480 |
Study First Received: | April 14, 2004 |
Last Updated: | December 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00081510 |
Health Authority: | United States: Food and Drug Administration |
Anastrozole Skin Diseases Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Hormonal Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Aromatase Inhibitors Pharmacologic Actions |